Anti-MET agonist antibody for use in the treatment of colorectal cancer

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11834507
APP PUB NO 20210087281A1
SERIAL NO

16959713

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to treatment of cancer using agonist anti-MET antibodies or fragments thereof. In particular, the invention relates to treatment of colorectal cancer using agonist anti-MET antibodies or fragments, typically colorectal cancer associated with chronic inflammation and/or gene mutations in the colon and in the gastrointestinal tract in general. The invention further relates to treating intestinal fibrosis using agonist anti-MET antibodies.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
AGOMAB THERAPEUTICSFRANKLIN ROOSEVELTLAAN 348 GENT 9000

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Michieli, Paolo Rivalta di Torino, IT 18 66

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Jun 5, 2027
7.5 Year Payment $3600.00 $1800.00 $900.00 Jun 5, 2031
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 5, 2035
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00